Advancing Innovative Immune-Oncology Technologies

We are a biopharmaceutical company focused on advancing proprietary technology platforms across multiple high-value cancer indications.

More About Us

Targeting Neutrophil Extracellular Traps (NETs)

NETs are a driver of cancer progression and metastasis and can also contribute to resistance to chemotherapy, checkpoint inhibitors and radiotherapy.

DNase I Oncology Platform

Oncology platform aimed at improving cancer therapies with the opportunity to address multiple oncology indications, including pancreatic cancer and other solid tumors.


Stock InformationView Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.
Day Range
52 Week Range
Investors Presentation

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today